Jump to main content
eTG Complete
Index
Search
Home
Cardiovascular
Heart failure
Heart failure with reduced ejection fraction (HFrEF)
Cardiovascular
Atherosclerotic cardiovascular disease risk estimation
Modifiable lifestyle risk factors for atherosclerotic cardiovascular disease
Lipid modification
Blood pressure reduction
Acute chest pain of possible cardiac origin
Acute coronary syndromes
Stable angina
Antithrombotic therapy after endovascular and cardiac interventions
Secondary prevention of atherosclerotic cardiovascular events
Peripheral artery disease
Pericarditis
Heart failure
Overview of heart failure
Heart failure with reduced ejection fraction (HFrEF)
General principles of drug therapy for HFrEF
Renin-angiotensin system inhibitors for HFrEF
Beta blockers for HFrEF
Mineralocorticoid receptor antagonists for HFrEF
Sodium-glucose co-transporter 2 inhibitors for HFrEF
Other drug therapies for HFrEF
References
Heart failure with mildly reduced ejection fraction (HFmrEF)
Heart failure with preserved ejection fraction (HFpEF)
Specialised therapy for refractory or advanced-stage heart failure
Acute cardiogenic pulmonary oedema
Arrhythmias in heart failure
Cardiac rehabilitation programs
Tachyarrhythmias
Bradyarrhythmias
Orthostatic hypotension
Pulmonary hypertension
Venous thromboembolism
Periprocedural management of patients with cardiovascular disease
Principles of anticoagulant therapy
Heart failure with reduced ejection fraction (HFrEF)
Published
June 2023
(Amended July 2024)
General principles of drug therapy for HFrEF
Renin-angiotensin system inhibitors for HFrEF
Beta blockers for HFrEF
Mineralocorticoid receptor antagonists for HFrEF
Sodium-glucose co-transporter 2 inhibitors for HFrEF
Other drug therapies for HFrEF
